Clinical trials: Post Transplant Diabetes
Chronic Pancreatitis, Diabetes Mellitus
Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation
The purpose of this study is to determine the effectiveness of closed loop insulin pump therapy to control blood sugar following total pancreatectomy and islet auto-transplantation (TPIAT).
- Trial name
- NCT01945138
- Testing
- Closed Loop Insulin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Prevention of New Onset Diabetes Among Kidney Transplant Patients
A Clinical Trial to Prevent New Onset Diabetes After Transplantation
Specific Aim 1: To determine the clinical efficacy of early initiation of insulin therapy in decreasing the incidence of NODAT among de novo kidney transplant patients with manifested post-transplant hyperglycemia during the…
- Trial name
- ITP-NODAT (NCT01683331)
- Testing
- Insulin treatment for hyperglycemia
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- University of Michigan
Pre Diabetes
Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation
Researchers are trying to determine if an anti-diabetes medication, called Exenatide SR, is well tolerated in kidney transplant patients with elevated blood glucose levels, and if it's effective in preventing diabetes.
- Trial name
- NCT03961256
- Testing
- Exenatide SR
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Pancreatitis, Diabetes
Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
The purpose of the study is to test the effects of sitagliptin on the need for insulin (the hormone that lowers blood sugars) by patients who receive a pancreatectomy and islet autotransplant for chronic pancreatitis.
- Trial name
- NCT01186562
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Minnesota
Wound
Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border
The clinical study will evaluate the safety and effectiveness of the ALLEVYN Gentle Border. The study is a post-market clinical follow-up to assess clinical performance and safety of ALLEVYN Gentle Border with new wound contact…
- Trial name
- NCT03877484
- Testing
- ALLEVYN Gentle border
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Smith & Nephew Orthopaedics AG
Kidney Transplant Recipients, Post-transplant Diabetes Mellitus
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients (KTR) with or without pre-existing type 2 diabetes (T2D)…
- Conditions
- Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes
- Trial name
- INFINITI2019 (NCT04965935)
- Testing
- Dapagliflozin 10 MG Oral Tablet
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Diabetes Mellitus, Type I
Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant.
- Trial name
- NCT00888628
- Testing
- Purified Pancreatic Islets, Etanercept
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Cardiovascular Disease, Chronic Kidney Disease
Vascular Risk After Kidney Transplantation
Hypothesis: Nontraditional risk factors, such as inflammation, vitamin D deficiency, elevated PTH, insulin resistance, homocysteine, or uric acid, contribute to cardiovascular disease progression after kidney transplant.
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency
- Trial name
- NCT00374595
- Where
- United States
- Volunteers
- 338 people
- Sponsor
- University of Nebraska
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Type 1 Diabetes
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a…
- Trial name
- NCT00533442
- Testing
- Rapamycin, Mycophenolate Mofetil, Tacrolimus
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Miami
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Type 2 Diabetes, End Stage Renal Disease
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
- Trial name
- NCT00936663
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Nebraska
Type 1 Diabetes
Incretin Effect and Use After Clinical Islet Transplantation
We aim to study if the administration of medications to increase the secretion of hormones from the intestines can improve glycemic control, reduce insulin use and promote β-cell regeneration/expansion in subjects with type 1…
- Trial name
- NCT00768651
- Testing
- Pantoprazole, Sitagliptin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Pancreatitis, Chronic; Diabetes; Transplant
Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Patients with severe chronic pancreatitis may be candidates to have their pancreas removed and their islets transplanted into the liver to reduce the risk of diabetes mellitus, a procedure called total pancreatectomy with islet…
- Trial name
- NCT02713997
- Testing
- etanercept, Alpha 1-Antitrypsin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Minnesota
Posttransplant Diabetes Mellitus
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
The purpose of this study is to determine whether sitagliptin is effective in preventing the development of new-onset diabetes after kidney transplant (NODAT).
- Trial name
- NCT01928199
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Kidney Transplant, Type 1 Diabetes
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
Patients meeting the study entry criteria will receive 1-3 infusion(s) of in vitro cultured islets. Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
- Trial name
- NCT02464878
- Testing
- Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who…
- Trial name
- NCT01206101
- Testing
- liraglutide
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 3 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Adult-Onset
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern immunosuppression.
- Trial name
- 01-DMPT (NCT01002339)
- Testing
- Tacrolimus with rapid steroid withdrawal, Tacrolimus with steroids minimization, CsA with steroid minimization
- Where
- 10 sites in Spain
- Volunteers
- 134 people
- Sponsor
- Armando Torres Ramírez
Diabetes Mellitus
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
- Trial name
- NCT01963728
- Testing
- Insulin, Isophane, insulin glargine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services
Diabetes, End Stage Renal Disease
Hyperglycemia in Renal Transplantation
Based on multiple prior studies, kidney transplant recipients with diabetes are at higher risk for poor initial graft function after transplant.
- Trial name
- HiRT (NCT01643382)
- Testing
- Insulin, Insulin, Asp(B28)-
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco